NCE

Processa Pharmaceuticals Issues Letter to Shareholders Highlighting Corporate Strategy, Drug Pipeline, and Outlook

Retrieved on: 
Wednesday, November 29, 2023

That will not change under my direction, and much of my experience is in oncology and leading business transactions.

Key Points: 
  • That will not change under my direction, and much of my experience is in oncology and leading business transactions.
  • However, many issues and limitations are associated with the use of chemotherapy.
  • Many patients simply cannot tolerate a chemotherapy dose high enough to benefit from its use due to chemotherapy’s toxic side effects.
  • Working in our favor are deep management and R&D teams that have significant and direct experience in clinical drug development.

PurMinds Appoints Leading Drug Designer, Dr. Alan Kozikowski, to Chief Scientific Officer and Appoints Pharma Veteran Dr. Max Arella to Scientific Advisory Board

Retrieved on: 
Thursday, November 9, 2023

Dr. Kozikowski is a Global leader in medicinal chemistry designing Novel Chemical Entities (NCEs) for oncology and neuroscience.

Key Points: 
  • Dr. Kozikowski is a Global leader in medicinal chemistry designing Novel Chemical Entities (NCEs) for oncology and neuroscience.
  • Dr. Arella is a seasoned drug development and technology transfer expert and former drug scout for big pharmaceutical companies.
  • Dr. Arella served as Chief Scientist and member of Scientific Advisory Boards of small, medium and large pharmaceuticals companies since 1996.
  • Previously PurMinds' acting CSO, Dr. Arella was instrumental in guiding PurMinds' business strategy in drug development.

Enveric Biosciences Receives Notice of Allowance from USPTO for Development of C4-Carbonothioate-substituted Tryptamine Derivatives for Novel Prodrug of Psilocin

Retrieved on: 
Tuesday, October 31, 2023

The soon-to-issue patent, titled, “C4-Carbonothioate-substituted Tryptamine Derivatives and Methods of Using,” contains composition of matter claims for a family of novel prodrug derivatives of psilocin, including EB-373, Enveric’s lead product candidate.

Key Points: 
  • The soon-to-issue patent, titled, “C4-Carbonothioate-substituted Tryptamine Derivatives and Methods of Using,” contains composition of matter claims for a family of novel prodrug derivatives of psilocin, including EB-373, Enveric’s lead product candidate.
  • The USPTO issues an NoA after making the determination that a patent should be granted from an application.
  • To date, the USPTO has issued seven NoAs for patent applications claiming compounds in the EVM201 and EVM301 Series.
  • Two applications are now granted patents that specifically protect EB-373; and one application is now a granted patent covering certain EVM301 compounds.

SEED Therapeutics Discloses Novel Molecular Glue IND Candidate for Cancer at “Targeted Protein Degradation Think Tank” Symposium

Retrieved on: 
Thursday, October 26, 2023

SEED is a subsidiary of BeyondSpring, Inc. (NASDAQ: BYSI), a clinical-stage biopharmaceutical company focusing on developing innovative therapies.

Key Points: 
  • SEED is a subsidiary of BeyondSpring, Inc. (NASDAQ: BYSI), a clinical-stage biopharmaceutical company focusing on developing innovative therapies.
  • According to Dr. Huang, “The SEED TPD Think Tank shared key TPD developments across academia and industry.
  • Their research, insight, and conviction allow SEED to focus and accelerate basic research into a fast-expanding TPD drug pipeline, enabled by our unique ability to identify the right E3.
  • This symposium provided a valuable exchange on new directions, opportunities, and challenges on TPD drug development.

Biolexis Therapeutics launches subsidiary Metabolexis to develop novel oral medicines for Obesity and Type 2 Diabetes to improve human longevity

Retrieved on: 
Thursday, October 26, 2023

AMERICAN FORK, Utah, Oct. 26, 2023 /PRNewswire/ -- Biolexis Therapeutics, a clinical-stage AI-enabled drug discovery company, today announced the launch of Metabolexis, a new pipeline company developing three targeted oral small molecules for the treatment of Obesity and Type 2 Diabetes, with the potential to improve human Longevity.

Key Points: 
  • Metabolexis focuses on GLP-1 weight loss and type 2 diabetic drug discoveries to improve accessibility and meet unprecedented demand.
  • AMERICAN FORK, Utah, Oct. 26, 2023 /PRNewswire/ -- Biolexis Therapeutics, a clinical-stage AI-enabled drug discovery company, today announced the launch of Metabolexis, a new pipeline company developing three targeted oral small molecules for the treatment of Obesity and Type 2 Diabetes, with the potential to improve human Longevity.
  • The World Health Organization estimates 650 million obese and 537 million Type 2 Diabetic patients worldwide.
  • The World Obesity Federation predicts that 51% of the world — more than 4 billion people — will be obese or overweight within the next 12 years.

Lubrizol’s Apisolex™ Polymer Wins Finished Formulation Award at CPhI Barcelona

Retrieved on: 
Wednesday, October 25, 2023

Apisolex™ Polymer is the first solubility-enhancing excipient to be launched specifically for parenteral use in over 20 years. Comprised of building blocks naturally occurring in the body, Apisolex™ is a poly(amino acid)--based excipient that provides drug formulators with the necessary tools and methods to enhance the solubility of hydrophobic APIs by up to 50,000-fold.

Key Points: 
  • Lubrizol Life Science Health, a leading pharmaceutical company, has won the Finished Formulation Award at CPhI Barcelona for its innovative technology – Apisolex™ Polymer solubilizing excipient.
  • The winners were announced at a networking reception held at CPhI Barcelona with over 500 guests in attendance.
  • View the full release here: https://www.businesswire.com/news/home/20231024985629/en/
    Kevin Song, Ph.D., Global Marketing Director accepts CPhI Award for Apisolex™ Polymer on behalf of The Lubrizol Corporation.
  • (Photo: Business Wire)
    Apisolex™ Polymer is the first solubility-enhancing excipient to be launched specifically for parenteral use in over 20 years.

Enhancing FTTR Experience Through Huawei iMaster NCE's Technical Innovations

Retrieved on: 
Wednesday, October 25, 2023

DUBAI, UAE, Oct. 25, 2023 /PRNewswire/ -- At the Ultra-Broadband Forum 2023 (UBBF 2023) recently held in Dubai, UAE, Huawei demonstrated a series of technology innovations based on the "A-PRIME" value proposition and introduced how Huawei iMaster NCE (Manager+Controller+Analyzer) helps carriers deliver a premium FTTR service experience.

Key Points: 
  • DUBAI, UAE, Oct. 25, 2023 /PRNewswire/ -- At the Ultra-Broadband Forum 2023 (UBBF 2023) recently held in Dubai, UAE, Huawei demonstrated a series of technology innovations based on the "A-PRIME" value proposition and introduced how Huawei iMaster NCE (Manager+Controller+Analyzer) helps carriers deliver a premium FTTR service experience.
  • Huawei iMaster NCE provides intelligent capabilities throughout the entire FTTR service process, to deliver premium services in marketing, deployment, and acceptance, as well as a premium gigabit user experience.
  • Coverage Visualization for Marketing: In terms of marketing, Huawei iMaster NCE provides the function of visualizing the network coverage based on subscription packages.
  • Huawei will continue to focus on user experience improvement through technical innovations, help improve network intelligence, and drive high-quality gigabit experience to a new level.

Huawei's iMaster NCE T-AUTO Unleashes the Business Potential of the WDM Network

Retrieved on: 
Friday, October 20, 2023

To address this challenge, Huawei's Optical Network Domain proposes T-AUTO as the brand-new value proposition.

Key Points: 
  • To address this challenge, Huawei's Optical Network Domain proposes T-AUTO as the brand-new value proposition.
  • T-AUTO 's multiple functions will be integrated into various scenarios, enabling key roles in business processes such as the marketing department, O&M department, and network department.
  • Huawei's iMaster NCE-T provides recommendations for private lines based on multiple dimensions to meet diverse network requirements for DCI.
  • Lu Chi, the Vice President of Huawei's NCE Optical Network Domain, emphasized that T-AUTO will remain a concept focusing on key requirements during network evolution.

Fabre-Kramer Pharmaceuticals Announces FDA Approval of EXXUA™, the First and Only Oral Selective 5HT1a Receptor Agonist for the Treatment of Major Depressive Disorder in Adults

Retrieved on: 
Thursday, September 28, 2023

HOUSTON, Sept. 28, 2023 /PRNewswire/ -- Fabre-Kramer Pharmaceuticals Inc. (Fabre-Kramer), a biopharmaceutical company committed to developing novel therapies to address unmet needs in psychiatry and neurology, is pleased to announce that the U.S. Food and Drug Administration (FDA) has approved Exxua™ (gepirone hydrochloride extended-release tablets) for the treatment of major depressive disorder (MDD) in adults. Exxua represents a new class of antidepressant; the first and only approved antidepressant with a novel mechanism of action that selectively targets the serotonin 1A receptor, a key regulator of mood and emotion. Exxua has been shown to effectively relieve depressive symptoms, and its approved labeling does not contain Warnings or Adverse Reactions regarding causing sexual dysfunction or weight gain vs. placebo. Exxua is expected to be available in pharmacies in early 2024.

Key Points: 
  • EXXUA is the first new chemical entity (NCE) utilizing this single mechanism approved for the treatment of major depressive disorder.
  • Exxua has been shown to effectively relieve depressive symptoms, and its approved labeling does not contain Warnings or Adverse Reactions regarding causing sexual dysfunction or weight gain vs. placebo.
  • Studied in over 5,000 patients, EXXUA's unique mechanism of targeted single serotonin (5HT) 1a receptor agonism relieves depressive symptoms with an acceptable side effect profile.
  • Over 20 million American adults experienced major depressive disorder each year prior to the COVID-19 pandemic.

PurMinds Acquires Novel Chemical Entity HDAC6 Inhibitor for Neurological Disorders

Retrieved on: 
Thursday, September 28, 2023

Toronto, Ontario--(Newsfile Corp. - September 28, 2023) - PurMinds NeuroPharma ("PurMinds" or the "Company"), a neuroscience company with a robust clinical pipeline combining small molecules, psychedelic compounds and other modalities, pursuing breakthrough therapeutic solutions for neurological disorders hallmarked by neurodegeneration, today announced completion of acquisition of a small molecule novel chemical entity (NCE) known as SW-200, a non-hydroxamic acid that shows superior histone deacetylase 6 (HDAC6) selectivity.

Key Points: 
  • Toronto, Ontario--(Newsfile Corp. - September 28, 2023) - PurMinds NeuroPharma ("PurMinds" or the "Company"), a neuroscience company with a robust clinical pipeline combining small molecules, psychedelic compounds and other modalities, pursuing breakthrough therapeutic solutions for neurological disorders hallmarked by neurodegeneration, today announced completion of acquisition of a small molecule novel chemical entity (NCE) known as SW-200, a non-hydroxamic acid that shows superior histone deacetylase 6 (HDAC6) selectivity.
  • Drugs that inhibit the molecular target HDAC6 are a novel class of therapeutics that are able to functionally enhance the axonal transport of nutrients, growth factors and neurotransmitters in neurons.
  • Encouraged by scientific studies that have shown efficacy in rodent models of neurodegenerative disorders, PurMinds NeuroPharma anticipates the successful development of an HDAC6 inhibitor for Charcot-Marie Tooth Disease (CMT) - a progressive neurodegenerative disorder, which causes disabling deficits in nerve function affecting 1 in 2500 people with no current cure.
  • "HDAC6 inhibition represents an innovative therapeutic target to address a range of neurological conditions currently without a cure.